0001625101-21-000006.txt : 20210203 0001625101-21-000006.hdr.sgml : 20210203 20210203161335 ACCESSION NUMBER: 0001625101-21-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210203 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulse Biosciences, Inc. CENTRAL INDEX KEY: 0001625101 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 465696597 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37744 FILM NUMBER: 21586348 BUSINESS ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 510-906-4600 MAIL ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 FORMER COMPANY: FORMER CONFORMED NAME: Electroblate, Inc. DATE OF NAME CHANGE: 20141113 8-K 1 plse-20210203x8k.htm 8-K plse-20210203x8k
false000162510100016251012021-02-032021-02-03

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

____________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 3, 2021

____________________

Pulse Biosciences, Inc.

(Exact name of registrant as specified in its charter)

____________________

 

Delaware

 

001-37744

 

46-5696597

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

3957 Point Eden Way

Hayward, California 94545

(Address of principal executive offices) (Zip code)

(510) 906-4600

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PLSE

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒ 

 

ITEM 8.01 OTHER EVENTS.

On February 3, 2021, Pulse Biosciences, Inc. issued a press release announcing U.S. Food and Drug Administration clearance for use of its CellFX System for dermatologic procedures requiring ablation and resurfacing of the skin.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d)

 Exhibits.

Exhibit No.

 

Description

99.1

 

Press Release issued by Pulse Biosciences, Inc. dated February 3, 2021.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)


‎

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PULSE BIOSCIENCES, INC.

 

By:  

/s/ Sandra A. Gardiner

Sandra A. Gardiner

Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer

(Principal Financial and Accounting Officer)

Date: February 3, 2021

 

 EX-99.1 2 plse-20210203xex99_1.htm EX-99.1 Exhibit 991

Pulse Biosciences Announces FDA Clearance for the CellFX® System



- CellFX System delivers Nano-Pulse Stimulation Technology in dermatologic procedures

- U.S. controlled launch to commence



HAYWARD, Calif. [Business Wire]– February 3, 2021. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of the CellFX System for dermatologic procedures requiring ablation and resurfacing of the skin. In the coming weeks a controlled commercial launch in the U.S. will begin with a group of selected Key Opinion Leaders (KOLs) in aesthetic dermatology.



“The CellFX System offers a unique non-thermal mechanism that in my experience can clear epidermal and mid-dermal cellular structures without damaging the non-cellular dermal collagen, which can lead to remarkable improvements in common skin problems that I see every day,” said Brian Zelickson, MD, Founder and Medical Director, Zel Skin and Laser Specialists in Edina, Minnesota. “We look forward to adding the CellFX System to our practice and foresee a promising future of new applications for this versatile technology platform.”



The CellFX System is a multi-application platform that harnesses the Company’s proprietary NPS technology delivering nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. NPS technology provides the ability to clear unwanted cellular structures while limiting collateral damage to the surrounding healthy skin, resulting in the potential to clear cellular skin structures with aesthetically pleasing outcomes.



“FDA clearance for the CellFX System is a tremendous achievement for Pulse Biosciences. We received the indication we were pursuing and believe this will be the first of many in this stepwise approach with FDA. This continued progress on our regulatory strategy, following the recent receipt of the CE mark, is another strong validation of the safety and efficacy of our technology. We are proud of our team and thankful to the investigators and FDA for their diligent efforts as part of this accomplishment,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “We look forward to proceeding with our Controlled Launch program with KOLs in the United States. This measured approach to launching the CellFX System is our top priority for 2021 and will be key to long-term commercial success of the CellFX platform.”



About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.



To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.



Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.



 

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of regulatory filings or approvals, NPS technology including the effectiveness of such technology, the CellFX System including the benefits of the CellFX System and commercialization and adoption of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Company’s market opportunity and commercialization plans, including the timing and results of the controlled launch in the US, the market for the treatment of certain lesions, the experience of using the CellFX System, future financial performance, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.



Contacts

Investors:

Pulse Biosciences

Sandra Gardiner, EVP and CFO

510.241.1077

IR@pulsebiosciences.com

or
Gilmartin Group
Philip Trip Taylor

415.937.5406
philip@gilmartinir.com



Media:
Tosk Communications
Nadine D. Tosk

504.453.8344

nadinepr@gmail.com or
press@pulsebiosciences.com



EX-101.SCH 3 plse-20210203.xsd EX-101.SCH 00090 - Document - Document And Entity Informationlink:presentationLinklink:calculationLinklink:definitionLink EX-101.LAB 4 plse-20210203_lab.xml EX-101.LAB EX-101.PRE 5 plse-20210203_pre.xml EX-101.PRE XML 6 plse-20210203x8k_htm.xml IDEA: XBRL DOCUMENT 0001625101 2021-02-03 2021-02-03 false 0001625101 8-K 2021-02-03 Pulse Biosciences, Inc. DE 001-37744 46-5696597 3957 Point Eden Way Hayward CA 94545 510 906-4600 false false false false Common Stock, par value $0.001 per share PLSE NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information
Feb. 03, 2021
Document And Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Feb. 03, 2021
Entity Registrant Name Pulse Biosciences, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37744
Entity Tax Identification Number 46-5696597
Entity Address, Address Line One 3957 Point Eden Way
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 906-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol PLSE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Entity Central Index Key 0001625101
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports plse-20210203x8k.htm plse-20210203.xsd plse-20210203_lab.xml plse-20210203_pre.xml plse-20210203xex99_1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "plse-20210203x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "plse-20210203x8k.htm" ] }, "labelLink": { "local": [ "plse-20210203_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "plse-20210203_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "plse-20210203.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "plse", "nsuri": "http://www.pulsebiosciences.com/20210203", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "plse-20210203x8k.htm", "contextRef": "Duration_2_3_2021_To_2_3_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document And Entity Information", "role": "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "plse-20210203x8k.htm", "contextRef": "Duration_2_3_2021_To_2_3_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.pulsebiosciences.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "plse_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.pulsebiosciences.com/20210203", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001625101-21-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001625101-21-000006-xbrl.zip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end